Medication Management in Stage 3a CKD (GFR 46.6)
Continue lisinopril 20 mg daily without dose adjustment, as no reduction is required until creatinine clearance falls below 30 mL/min, and maintain furosemide, metoprolol, and hydralazine at current doses while monitoring renal function and electrolytes every 2-4 weeks. 1
ACE Inhibitor Management (Lisinopril)
Your patient's GFR of 46.6 mL/min/1.73m² falls in the Stage 3a CKD range, which is above the threshold requiring lisinopril dose adjustment. According to FDA labeling, lisinopril dose reduction is only necessary when creatinine clearance drops to ≤30 mL/min 1. At your patient's current renal function:
- No dose adjustment needed for the 20 mg daily dose
- Continue current therapy unless contraindications develop
- The KDIGO 2024 guidelines explicitly state to continue ACE inhibitors even when eGFR falls below 30 mL/min/1.73m² 2
Critical Monitoring Parameters
Within 2-4 weeks of any dose change (or now if not recently checked), assess 2, 3:
- Serum creatinine (discontinue only if rises >30% within 4 weeks)
- Serum potassium (hyperkalemia can often be managed with potassium binders rather than stopping the ACE inhibitor)
- Blood pressure (watch for symptomatic hypotension)
Key caveat: The only scenarios requiring lisinopril dose reduction or discontinuation at this GFR are 2, 3:
- Symptomatic hypotension despite management
- Uncontrolled hyperkalemia despite potassium-lowering interventions
- Serum creatinine rise >30% within 4 weeks of initiation/dose increase
Loop Diuretic Management (Furosemide)
Furosemide 20 mg daily requires no dose adjustment at GFR 46.6. Loop diuretics remain effective and are often necessary in CKD for volume management 4. However, monitor closely for:
- Volume depletion (which can worsen renal function)
- Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia)
- Ototoxicity risk if combined with aminoglycosides
The combination of furosemide with lisinopril is appropriate but increases hypotension risk—ensure the patient is not volume-depleted 4.
Beta-Blocker and Vasodilator Management
Metoprolol ER 12.5 mg daily and hydralazine 25 mg twice daily require no renal dose adjustments, as neither is primarily renally eliminated. Continue current doses.
Essential Additions to Consider
Based on KDIGO 2024 guidelines, your patient may benefit from 2:
SGLT2 Inhibitor
- Strongly recommended if the patient has:
- Diabetes with eGFR ≥20 (Grade 1A recommendation)
- Heart failure (Grade 1A recommendation)
- Albuminuria ≥200 mg/g (Grade 1A recommendation)
- Consider even with eGFR 20-45 and albuminuria <200 mg/g (Grade 2B recommendation)
Assess Albuminuria Status
If not already done, check urine albumin-to-creatinine ratio to determine:
- Whether to maximize lisinopril dose (highest tolerated dose recommended for albuminuric CKD) 2
- Eligibility for SGLT2 inhibitor or nonsteroidal MRA (finerenone)
Monitoring Schedule
Establish regular monitoring 2, 3:
- Every 2-4 weeks after any medication changes: creatinine, potassium, BP
- Every 3-6 months when stable: comprehensive metabolic panel, albuminuria
- Annually: lipid panel, assess for CKD complications
Common Pitfalls to Avoid
Do not reduce lisinopril dose prematurely—it provides renoprotection and should be continued even as GFR declines to <30 unless specific contraindications arise 2
Do not stop ACE inhibitor for mild hyperkalemia—use dietary potassium restriction and potassium binders (patiromer, sodium zirconium cyclosilicate) first 2
Do not overlook volume status—the combination of ACE inhibitor and diuretic increases hypotension risk, particularly if the patient becomes volume-depleted 1, 4
Do not miss the opportunity to add SGLT2 inhibitor—these agents provide significant cardiovascular and renal protection independent of their modest BP-lowering effects 2